Azithromycin is one of the most widely prescribed antibiotics in the world, valued for its short course and generally mild side effects. In 2012, a large study from Vanderbilt University reported that people taking it had a small but measurable increase in the risk of dying from a cardiovascular cause during the days they were on the drug, and in 2013 the U.S. Food and Drug Administration strengthened its warning about abnormal heart rhythms. This article explains what that study actually showed, how large the risk is in absolute terms, what the FDA said and why, how the evidence has held up in the decade since, and which patients with existing heart problems have the most reason to discuss alternatives with their own physician.

A soil-derived medicine and how it touches the heart

Azithromycin belongs to the macrolide family. Its parent compound, erythromycin, was isolated around 1950 from a bacterium found in a soil sample from the Philippines, and azithromycin itself was developed by chemists in Croatia in 1980 by modifying that molecule to make it more stable and longer lasting. It is a fair reminder that some of our most useful medicines come from organisms quietly living in the ground beneath us, waiting to be discovered by careful observation. Azithromycin stops bacteria from making proteins, and it concentrates in tissues so well that a three- or five-day course keeps working for days afterward; its elimination half-life is roughly two to three days.

The heart concern relates to the QT interval, a measurement on an electrocardiogram (ECG) that reflects how long the heart's lower chambers take to electrically "reset" after each beat. That recovery is a finely balanced process governed by ion channels in the heart muscle cell membrane. When the QT interval becomes excessively long, the heart can, rarely, slip into a chaotic rhythm called torsades de pointes, which can degenerate into ventricular fibrillation and sudden death.

Laboratory studies in isolated cells show that macrolides partially block a potassium channel (often called hERG) that is central to this reset. Azithromycin blocks it more weakly than erythromycin or clarithromycin. Later cell and animal work, including research published in Circulation in 2017, suggested azithromycin may also increase a "late" sodium current in heart cells, a second route to prolonged repolarisation. These mechanistic findings are plausible explanations, but they come from cell cultures and mice; they help explain the human data rather than prove risk on their own. In people, azithromycin's effect on the QT interval in healthy volunteers is modest. The concern is concentrated in those whose heart rhythm reserve is already reduced.

What the 2012 Vanderbilt study found

The study that brought this issue to public attention was led by Wayne Ray and colleagues at Vanderbilt University and published in the New England Journal of Medicine in May 2012. It was a retrospective cohort study using Tennessee Medicaid records from 1992 to 2006, covering roughly 348,000 azithromycin prescriptions along with millions of comparison periods. The researchers deliberately excluded people with serious non-cardiac illness and compared azithromycin users with matched people taking no antibiotic and with people taking amoxicillin, ciprofloxacin or levofloxacin.

The key findings were:

Those last two numbers are the heart of the matter. For a healthy young adult, the added risk is very small. For an older person with established heart disease, it is still uncommon but meaningfully larger, and it is exactly that group for whom the choice of antibiotic deserves thought.

The study's strengths were its size, its careful comparison with other antibiotics given for similar infections, and its time-limited signal that matched the drug's known pharmacology. Its limitations are those of any observational study: it could not randomise patients, cause of death was taken from records rather than confirmed by autopsy, and the Medicaid population is not identical to the general public. Infection itself stresses the heart, and people prescribed one antibiotic may differ in unmeasured ways from those prescribed another.

The FDA warning and whom it singles out

The FDA issued a statement acknowledging the study shortly after publication, and in March 2013 released a Drug Safety Communication stating that azithromycin can cause abnormal changes in the heart's electrical activity that may lead to a potentially fatal irregular rhythm. The agency drew on the Vanderbilt data and on an ECG study conducted by the manufacturer, and the drug's labelling was updated. The warning did not tell patients to stop taking azithromycin; it asked prescribers to consider the risk when choosing among antibacterial drugs, particularly for patients already vulnerable.

The groups the FDA identified as at particular risk include people with:

The labelling also notes that older adults may be more susceptible. Many common medicines, including certain antidepressants, antipsychotics, anti-nausea drugs and antifungals, also lengthen the QT interval, so the risk is often about combinations rather than azithromycin alone. One practical advantage is that azithromycin, unlike clarithromycin and erythromycin, only weakly interferes with the liver enzyme CYP3A4, so it causes fewer interactions that raise other drugs' blood levels. The QT effects, however, can still add together.

How the evidence has held up since 2012

Subsequent research has both supported and complicated the original signal, which is how medical knowledge usually matures.

A Danish nationwide cohort by Henrik Svanström and colleagues, published in the New England Journal of Medicine in 2013, examined adults aged 18 to 64. Compared with no antibiotic, azithromycin was again associated with a roughly 2.9-fold higher rate of cardiovascular death during treatment. But compared with penicillin V, a drug given for similar infections, there was no significant difference. This suggests that in younger, healthier populations much of the apparent risk may reflect the infection rather than the drug, and that any true drug effect in such people is very small.

A U.S. Veterans Affairs cohort published in the Annals of Family Medicine in 2014, in a predominantly older male population, found azithromycin associated with a higher short-term risk of death and serious arrhythmia than amoxicillin during the first five days, with levofloxacin showing a larger increase. Another Veterans Affairs study in JAMA the same year looked at older patients hospitalised with pneumonia and found that azithromycin-containing regimens were associated with lower 90-day mortality overall, alongside a small increase in heart attacks and no significant increase in arrhythmias. For serious pneumonia, in other words, the benefit of effective treatment appears to outweigh the cardiac cost for most patients.

Randomised trials offer some reassurance, with caveats. In the ACES and WIZARD trials of the early 2000s, thousands of patients with coronary artery disease received azithromycin for months in an unsuccessful attempt to prevent heart attacks; neither found an excess of cardiac deaths. A large 2011 New England Journal of Medicine trial of daily azithromycin in chronic obstructive pulmonary disease likewise did not show excess cardiovascular death, though it excluded patients with prolonged QT intervals and noted hearing loss as a side effect. Trials enrol selected, monitored patients and may lack the size to detect rare deaths, so they temper rather than refute the observational findings.

In 2020, the combination of azithromycin with hydroxychloroquine for COVID-19 drew fresh attention to QT risk, as hospital studies documented marked QT prolongation in some patients receiving both. That combination is not an approved treatment for COVID-19, and the episode underscored how QT effects compound.

The fair summary is this: azithromycin carries a real but small risk of fatal arrhythmia, concentrated in people with existing heart disease, electrolyte problems or interacting medicines. For most healthy people, the added risk is too small to measure reliably.

Stewarding your own heart: questions to bring to your doctor

Caring for one's health is a matter of stewardship, not fear. A life has worth at every age and in every state of health, and an older patient with a weak heart deserves the same careful thought as anyone else. The practical goal is an honest conversation with your own physician or pharmacist, who knows your history far better than any general guideline can. Useful questions include:

Keeping an up-to-date list of every medication and supplement you take, and carrying it to every appointment, is one of the simplest protective steps a patient or family caregiver can take. It is also wise to know the warning signs that warrant urgent medical attention while on treatment: fainting, a racing or pounding heartbeat, or sudden dizziness. Patients should not stop a prescribed antibiotic on their own; the right response to concern is a conversation, not a unilateral decision. This article is general information and does not replace individual advice from a clinician who knows your situation.

Key takeaway: Azithromycin's heart risk is real but small, and it matters most for people with existing heart disease, low potassium or magnesium, or other QT-prolonging medicines, who should talk with their own doctor about whether it is the best choice for them.